JAK1 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Myogenesis Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Cyclin D associated events in G1 RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX2 regulates osteoblast differentiation FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	ATP Imatinib Dasatinib N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide Nilotinib XL228 Bosutinib 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA Myristic acid PD-166326 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide Regorafenib Ponatinib Fostamatinib Brigatinib Radotinib Asciminib Umbralisib	Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Chronic myeloid leukemia (CML)
Novel	AGTR1	angiotensin II receptor type 1	Peptide ligand-binding receptors G alpha (q) signalling events Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Valsartan Olmesartan Losartan Candesartan cilexetil Eprosartan Telmisartan Irbesartan Forasartan Saprisartan Tasosartan CYT006-AngQb Azilsartan medoxomil Fimasartan Angiotensin II Candesartan	Renal tubular dysgenesis
Novel	ANKRD13C	ankyrin repeat domain 13C
Novel	BRCA1	BRCA1 DNA repair associated	Meiotic synapsis SUMOylation of DNA damage response and repair proteins HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Metalloprotease DUBs Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Neddylation Transcriptional Regulation by E2F6 Meiotic recombination Defective DNA double strand break response due to BRCA1 loss of function Defective DNA double strand break response due to BARD1 loss of function Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence		Ovarian cancer Breast cancer
Novel	BTK	Bruton tyrosine kinase	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Potential therapeutics for SARS Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib Spebrutinib Fostamatinib Fenebrutinib Zanubrutinib Evobrutinib Tirabrutinib Abivertinib Branebrutinib Vecabrutinib	Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD) Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel	CBR1	carbonyl reductase 1	Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	Rutin Resveratrol Heptaethylene glycol 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400 Quercetin 3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol Curcumin Curcumin sulfate
Novel	CCR1	C-C motif chemokine receptor 1	Chemokine receptors bind chemokines G alpha (i) signalling events Interleukin-10 signaling
Novel	CCR5	C-C motif chemokine receptor 5	Binding and entry of HIV virion Chemokine receptors bind chemokines G alpha (i) signalling events Interleukin-10 signaling	Maraviroc AMD-070 CCR5 mAb Leronlimab Aplaviroc Vicriviroc Ibalizumab INCB-9471
Novel	CISH	cytokine inducible SH2 containing protein	Interleukin-7 signaling Neddylation Growth hormone receptor signaling
Novel	CSF2RB	colony stimulating factor 2 receptor subunit beta	Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF/MAP kinase cascade Surfactant metabolism Defective CSF2RB causes SMDP5 Defective CSF2RA causes SMDP4 Interleukin receptor SHC signaling	Sargramostim NPI 32101 Resatorvid
Novel	CSF3R	colony stimulating factor 3 receptor	Other interleukin signaling Transcriptional regulation of granulopoiesis Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling	Pegfilgrastim Filgrastim FavId Lenograstim Lipegfilgrastim Eflapegrastim
Novel	CXCR4	C-X-C motif chemokine receptor 4	Binding and entry of HIV virion Signaling by ROBO receptors Chemokine receptors bind chemokines G alpha (i) signalling events Formation of definitive endoderm Specification of primordial germ cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Baclofen Framycetin AMD-070 Plerixafor Ulocuplumab Ibalizumab MSX-122	Chemokine receptor defect, including the following disease: WHIM syndrome
Novel	DAB1	DAB adaptor protein 1	Reelin signalling pathway
Novel	DHX9	DExH-box helicase 9	RIP-mediated NFkB activation via ZBP1 DEx/H-box helicases activate type I IFN and inflammatory cytokines production mRNA Splicing - Major Pathway PKR-mediated signaling
Novel	EIF2AK2	eukaryotic translation initiation factor 2 alpha kinase 2	ISG15 antiviral mechanism Inhibition of PKR SUMOylation of immune response proteins Interferon alpha/beta signaling Evasion by RSV of host interferon responses PKR-mediated signaling	Indomethacin H-89 Fostamatinib
Novel	ELP2	elongator acetyltransferase complex subunit 2	HATs acetylate histones
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
Novel	FER	FER tyrosine kinase	Signaling by SCF-KIT	Fostamatinib
Novel	FES	FES proto-oncogene, tyrosine kinase	Signaling by SCF-KIT Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling	Fostamatinib
Novel	GAB1	GRB2 associated binding protein 1	PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants

Search Results for: JAK1